Hutchison China Meditech Ltd (HCM)


HCM Share PerformanceMore

52 week high3,335.75 20/03/17
52 week low1,612.50 28/04/16
52 week change 1,095.00 (57.48%)
4 week volume437,984 26/02/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Chi-Med chief scientific officer joins board

Hutchison China MediTech has appointed Dr Weiguo Su as an executive director and member of the technical committee...

Appointment of Director

RNS Number: 4316A Hutchison China Meditech Limited 24 March 2017 Appointment of Director London: Friday, March 24 , 2017: Hutchison China MediTech Limited ("Chi-Med")or the ("Company") (AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been appointed as E xecutive Director and member of Technical Committee with effect from March 27...

Chi-Med to host R&D Briefings

RNS Number: 0625A Hutchison China Meditech Limited 21 March 2017 Press Release Chi-Med to host R&D Briefings on March 29 & 30, 2017 London: Tuesday, March 21, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it will host Research & Development ("R&D") briefings in London and New York to provide an o...

Director Deals - Hutchison China Meditech Ltd (HCM)

Paul Carter, Non Executive Director, bought 2,800 shares in the company on the 15th March 2017 at a price of 2637.00p. Th...

Directors' Share Dealing

RNS Number: 9126Z Hutchison China Meditech Limited 20 March 2017 Directors' Share Dealing London: Monday, March 20 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:- 1. Mr Paul Carter, Independent Non-executive Director, purchased a total of 2,800 ordinary shares of US$1.00 each in the capital of Ch...

Grant of Awards under Long Term Incentive Plan

RNS Number: 6898Z Hutchison China Meditech Limited 16 March 2017 Press release Grant of Awards under Long Term Incentive Plan London: Thursday , March 1 6 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on March 15, 2017 , it granted conditional awards ("LTIP Awards") under the Long Term Incentive Plan ("L...

Hutchison China MediTech shares tipped to hit record high

There are high hopes for Chi-Med's big cancer drug and City experts say the shares are undervalued. Graeme Evans report...

Higher commodity prices boost FTSE as May considers triggering Article 50

Takeover activity among mid-cap stocks dominated the market on Monday, while speculation grew that UK Prime Minist...

Equity Research (HCM)

edison investment research
Hutchison China MediTech Limited
Hutchison (HCM) and partner Lilly announced positive, top-line pivotal phase III trial results for fruquintinib in 3rd line colorectal cancer. The China based FRESCO study evaluating 416 patients who...
edison investment research
Hutchison China MediTech Limited
Hutchison (HCM) and partner AstraZeneca presented positive preliminary data from the ongoing phase II proof-of-concept trial evaluating savolitinib (c-Met TKI) in papillary renal cell carcinoma (PRCC...
Hutchison China MediTech Ltd.
Chi-Med’s CEO, Christian Hogg, delivered a confident and convincing presentation at the recent interim analyst meeting. It was certainly refreshing to hear a CEO explain a drop in profits (and doing...

Latest discussion posts More

Users' HoldingsMore

Users who hold Hutchison China Meditech Ltd also hold..
RDS 'B'26%

Codes & Symbols